Top

Cancer Chemotherapy and Pharmacology

Published in:

01-10-2013 | Review Article

Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung

Authors: Dong Wang, Licheng Du, Qi Liu, Xiangyan Liu, Zhou Wang

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2013

Abstract

Purpose

Targeted therapy has greatly improved the treatment for adenocarcinoma of the lung, but not squamous cell carcinoma (SCC) of the lung. The current paper describes the abnormalities of receptor tyrosine kinases (RTK) in lung SCC in a hope to stimulate the development of therapeutics that can have clinical impact.

Methods

We reviewed both clinical and preclinical studies published in English regarding RTK abnormalities and/or RTK-targeting treatment for SCC of the lung.

Results

RTK alterations have been demonstrated as biological signature for SCC of the lung. A number of clinical trials of RTK-targeting therapy have been carried out or are ongoing, with encouraging results.

Conclusions

SCC of the lung should be treated as an independent disease with unique treatment options based on molecular changes, particularly RTK.

Jemal A, Bray F, Center MM et al (2011) Global cancer statistics. CA Cancer J Clin 61(2):69–90PubMedCrossRef

Moran C (2011) Importance of molecular features of non-small cell lung cancer for choice of treatment. Am J Pathol 178(5):1940–1948PubMedCrossRef

Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98PubMedCrossRef

Erridge SC, Møller H, Price A et al (2007) International comparisons of survival from lung cancer: pitfalls and warnings. Nat Clin Pract Oncol 4(10):570–577PubMedCrossRef

Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550PubMedCrossRef

Hainsworth JD, Fang L, Huang JE et al (2011) BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol 6(1):109–114PubMedCrossRef

Sharma SV, Bell DW, Settleman J et al (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7(3):169–181PubMedCrossRef

Mason I (2007) Initiation to end point: the multiple roles of fibroblast growth factors in neural development. Nat Rev Neurosci 8(8):583–596PubMedCrossRef

Turner N, Grose R (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10(2):116–129PubMedCrossRef

10.

Haugsten EM, Wiedlocha A, Olsnes S et al (2010) Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8(11):1439–1452PubMedCrossRef

11.

Weiss J, Sos ML, Seidel D et al (2010) Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2(62):62ra93PubMedCrossRef

12.

Bass AJ, Watanabe H, Mermel CH et al (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41(11):1238–1242PubMedCrossRef

13.

Dutt A, Ramos AH, Hammerman PS et al (2011) Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE 6(6):e20351PubMedCrossRef

14.

Schildhaus HU, Heukamp LC, Merkelbach-Bruse S et al (2012) Definition of a fluorescence in situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol 25(11):1473–1480PubMedCrossRef

15.

Khandwala HM, McCutcheon IE, Flyvbjerg A et al (2000) The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 21(3):215–244PubMedCrossRef

16.

LeRoith D, Werner H, Beitner-Johnson D et al (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16(2):143–163PubMed

17.

Baserga R, Hongo A, Rubini M et al (1997) The IGF-I receptor in cell growth, transformation and apoptosis. Biochim Biophys Acta 1332(3):F105–F126PubMed

18.

Chitnis MM, Yuen JS, Protheroe AS et al (2008) The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14(20):6364–6370PubMedCrossRef

19.

Dziadziuszko R, Camidge DR, Hirsch FR (2008) The insulin-like growth factor pathway in lung cancer. J Thorac Oncol 3(8):815–818PubMedCrossRef

20.

Dziadziuszko R, Merrick DT, Witta SE et al (2010) Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression. J Clin Oncol 28(13):2174–2180PubMedCrossRef

21.

Cappuzzo F, Tallini G, Finocchiaro G et al (2010) Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Ann Oncol 21(3):562–567PubMedCrossRef

22.

Gualberto A, Dolled-Filhart M, Gustavson M et al (2010) Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition. Clin Cancer Res 16(18):4654–4665PubMedCrossRef

23.

Wong AJ, Ruppert JM, Bigner SH et al (1992) Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci USA 89(7):2965–2969PubMedCrossRef

24.

Ji H, Zhao X, Yuza Y et al (2006) Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci USA 103(20):7817–7822PubMedCrossRef

25.

Sasaki H, Kawano O, Endo K et al (2007) EGFRvIII mutation in lung cancer correlates with increased EGFR copy number. Oncol Rep 17(2):319–323PubMed

26.

Ostman A (2004) PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 15(4):275–286PubMedCrossRef

27.

Wu E, Palmer N, Tian Z et al (2008) Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS ONE 3(11):e3794PubMedCrossRef

28.

Rikova K, Guo A, Zeng Q et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131(6):1190–1203PubMedCrossRef

29.

Ramos AH, Dutt A, Mermel CH et al (2009) Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 8(21):2042–2050PubMedCrossRef

30.

Ikeda K, Wang LH, Torres R et al (2002) Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem 277(21):19206–19212PubMedCrossRef

31.

Olaso E, Labrador JP, Wang LH et al (2002) Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem 277(5):3606–3613PubMedCrossRef

32.

Hammerman PS, Sos ML, Ramos AH et al (2011) Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 1(1):78–89PubMedCrossRef

33.

Ebert M, Yokoyama M, Friess H et al (1994) Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer. Cancer Res 54(22):5775–5778PubMed

34.

Engelman JA, Zejnullahu K, Mitsudomi T et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039–1043PubMedCrossRef

35.

Go H, Jeon YK, Park HJ et al (2010) High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer. J Thorac Oncol 5(3):305–313PubMedCrossRef

36.

Forbes SA, Bindal N, Bamford S et al (2011) COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res 39(Database issue):D945–D950PubMedCrossRef

37.

Kong-Beltran M, Seshagiri S, Zha J et al (2006) Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66(1):283–289PubMedCrossRef

38.

Pasquale EB (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133(1):38–52PubMedCrossRef

39.

Brannan JM, Dong W, Prudkin L et al (2009) Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 15(13):4423–4430PubMedCrossRef

40.

Fang WB, Brantley-Sieders DM, Parker MA et al (2005) A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24(53):7859–7868PubMedCrossRef

41.

Larsen AB, Pedersen MW, Stockhausen MT et al (2007) Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 5(3):283–293PubMedCrossRef

42.

Kinch MS, Moore MB, Harpole DH Jr (2003) Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res 9(2):613–618PubMed

43.

Faoro L, Singleton PA, Cervantes GM et al (2010) EphA2 mutation in lung squamous cell carcinoma promotes increased cell survival, cell invasion, focal adhesions, and mammalian target of rapamycin activation. J Biol Chem 285(24):18575–18585PubMedCrossRef

44.

Andre F, Bachelot TD, Campone M et al (2011) A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. J Clin Oncol 29(suppl):abstr 508

45.

Dienstmann R, Andre F, Soria J et al (2012) Significant antitumor activity of E-3180, a novel FGFR and VEGFR inhibitor, in patients with FGFR1 amplified breast cancer. Ann Oncol 23(Suppl 9):ix116–ix143CrossRef

46.

Karp DD, Paz-Ares LG, Novello S et al (2009) Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol 27(15):2516–2522PubMedCrossRef

47.

Ito Y, Suenaga M, Hatake K et al (2012) Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: a Phase 1 dose-escalation study. Jpn J Clin Oncol 42(4):278–286PubMedCrossRef

48.

Socinski MA, Novello S, Brahmer JR et al (2008) Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 26(4):650–656PubMedCrossRef

49.

Shah GD, Loizos N, Youssoufian H et al (2010) Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. Cancer 116(4 Suppl):1018–1026PubMedCrossRef

50.

Day E, Waters B, Spiegel K et al (2008) Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol 599(1–3):44–53PubMedCrossRef

51.

Haura EB, Tanvetyanon T, Chiappori A et al (2010) Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol 28(8):1387–1394PubMedCrossRef

52.

Johnson FM, Bekele BN, Feng L et al (2010) Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 28(30):4609–4615PubMedCrossRef

53.

Beth AH, Gerald E, Nicholas JV et al (2012) Activity of cabozantinib (XL184) in metastatic NSCLC: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 30(suppl):abstr 7514

54.

Spigel DR, Ervin TJ, Ramlau R et al (2011) Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol 29(suppl):abstr 7505

55.

Sequist LV, von Pawel J, Garmey EG et al (2011) Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 29(24):3307–3315PubMedCrossRef

Title: Receptor tyrosine kinase alterations and therapeutic opportunities in squamous cell carcinoma of the lung
Authors: Dong Wang
Licheng Du
Qi Liu
Xiangyan Liu
Zhou Wang
Publication date: 01-10-2013
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2013
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-013-2252-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2013

Identification of two novel inhibitors of mTOR signaling pathway based on high content screening

A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer

Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells

Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib

Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer

Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers

Keynote webinar | Spotlight on antibody–drug conjugates in cancer